Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications

Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications

BEIJING, June 23, 2026 /PRNewswire/ -- On June 23, 2026 (Beijing time), Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive...

Haisco and Nuvectis sign licensing deal for two drugs

Nuvectis secured worldwide rights, outside specified Asian territories, to develop, manufacture and commercialise Haisco’s drug candidates HSK42360 and HSK39297. Haisco will receive $40m in upfront and near-term payments, The post Haisco and Nuvectis sign licensing deal for two drugs appeared first on Pharmaceutical Business review.

Haisco and Nuvectis sign licensing deal for two drugs

Haisco has signed an exclusive licensing agreement granting Nuvectis rights for two drug candidates in oncology and complement indications.The post Haisco and Nuvectis sign licensing deal for two drugs appeared first on Hospital Management.